Amgen, Inc.
http://www.amgen.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Amgen, Inc.
Long Wait Ahead For Novartis's Leqvio In US
The timeline for a US resubmission of the closely watched PCSK9-targeting cholesterol treatment could be either Q2 or Q3 and approval will depend on whether the FDA needs to make a physical inspection of an Italian facility.
Roche Prepares Faricimab For Filing After Phase III AMD Data
Top-line Phase III data for faricimab in age-related macular degeneration leave Roche poised to file the bi-specific antibody for retinal diseases, but again there is no advantage with the novel dual-acting product over Eylea.
Coronavirus Update: EU Demands AstraZeneca Meets Its Vaccines Commitments After Supply Warning
Plus Takeda starts vaccine trial in Japan and South Korea clears Celltrion's antibody therapeutic.
Merck & Co. Pivots To COVID-19 Treatments After Vaccines Disappoint
The company cited lackluster efficacy in its decision to discontinue development of V590 and V591. It will instead develop two drugs to treat COVID-19.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Abgenix
- Amgen Astellas BioPharma K.K.
- Amgen K.K.
- Avidia
- BioVex Group
- Catherex, Inc.
- deCODE Genetics
- Dezima Pharma B.V.
- Ilypsa
- Immunex Corporation
- KAI Pharmaceuticals
- Kirin-Amgen Inc.
- Laboratorio Quimico Farmaceutico Bergamo Ltd
- Micromet, Inc. (CancerVax Corporation)
- Nuevolution AB
- Nuevolution A/S
- Onyx Pharmaceuticals, Inc. (Proteolix, Inc.)
- Saga Investments LLC
- Tularik
- Dezima Pharma